Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Persistent Disease Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Vestibular Stimulation to Help Occasional Sleeplessness

NCT00594022
View directory record Official record
Conditions
Insomnia, Sleeplessness, Transient Insomnia
Interventions
Electric stimulation of the Vestibular Nerve - "VirtuSom", Electric stim of the Vestibular Nerve - "VirtuSom" - SHAM
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 50 Years
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
6
States / cities
Atlanta, Georgia • New York, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 2 Interventional

Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00054119
View directory record Official record
Conditions
Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Interventions
Cositecan, Pharmacological Study
Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 13, 2026, 9:32 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Low-dose Naltrexone in Chronic Migraine With Fibromyalgia

NCT05536050
View directory record Official record
Conditions
Chronic Migraine, Fibromyalgia, New Daily Persistent Headache
Interventions
Migraine diary and Questionnaires
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 13, 2026, 9:32 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

NCT03275740
View directory record Official record
Conditions
Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 13, 2026, 9:32 PM EDT
Active, not recruiting Not applicable Interventional

Mobile Subthreshold Exercise Program for Concussion--R01

NCT04688255
View directory record Official record
Conditions
Concussion, Brain, Concussion, Mild, Brain Injuries, Traumatic, Persistent Post Traumatic Headache, Post-Concussion Syndrome, Post-Concussive Syndrome, Chronic
Interventions
MSTEP, Stretching
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
11 Years to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

NCT01165138
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Placebo Inhaltion Powder
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Bell Gardens, California • Huntington Beach, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 2 Interventional

Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT00217555
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
gemcitabine hydrochloride, topotecan hydrochloride
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 4 Interventional Results available

Helping Those With Mental Illness Quit Smoking

NCT01783912
View directory record Official record
Conditions
Smoking, Nicotine Dependence, Mental Disorders
Interventions
Cognitive / Motivational Individual Sessions, Attention Control Individual Sessions, Nicotine Patch, Group Curriculum
Behavioral · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 13, 2026, 9:32 PM EDT
Withdrawn Not applicable Interventional

Reducing Problematic Substance Use in Youth With Chronic Medical Conditions

NCT01709201
View directory record Official record
Conditions
Alcohol Abuse, Drug Abuse
Interventions
Brief Intervention
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
14 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Sep 13, 2026, 9:32 PM EDT
Completed No phase listed Observational

The Role of Cardiac Biomarkers in Prediction of Outcome in Atrial Fibrillation Patients Undergoing Catheter Ablation

NCT01148914
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Inflammatory biomarkers
Other
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 13, 2026, 9:32 PM EDT
Not listed Phase 1Phase 2 Interventional

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

NCT00003064
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, carboplatin, etoposide phosphate, paclitaxel, thiotepa, topotecan hydrochloride, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 1 Interventional

A Study of AL721 in HIV-Infected Patients With Swollen Lymph Nodes

NCT00001012
View directory record Official record
Conditions
HIV Infections
Interventions
AL 721
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Los Angeles, California • New Orleans, Louisiana • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Not applicable Interventional

Mobile CHESS Research on Emergency Medical Services for Children

NCT00993590
View directory record Official record
Conditions
Asthma
Interventions
M CHESS
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Years to 18 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 13, 2026, 9:32 PM EDT
Completed No phase listed Observational

Severe Asthma Research Program - Wake Forest University

NCT01750411
View directory record Official record
Conditions
Asthma, Severe Persistent Asthma
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
6 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 13, 2026, 9:32 PM EDT
Active, not recruiting Not applicable Interventional

Promoting Activity and Cognitive Enrichment in Schizophrenia (PACES)

NCT04143126
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Enhancement Therapy, Enriched Supportive Therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT00723255
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma
Interventions
bevacizumab, temsirolimus
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
41
States / cities
Hartford, Connecticut • New Britain, Connecticut • Washington D.C., District of Columbia + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 13, 2026, 9:32 PM EDT
Terminated Phase 3 Interventional Results available

SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

NCT01760889
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
4
States / cities
Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 13, 2026, 9:32 PM EDT
Terminated Not applicable Interventional

Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion

NCT00584662
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
Oxymetazoline Hydrochloride
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

NCT00509691
View directory record Official record
Conditions
Cancer
Interventions
cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis, flow cytometry, immunologic technique
Biological · Genetic · Other
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00872989
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
docetaxel, vandetanib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
137
States / cities
Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2016 · Synced Sep 13, 2026, 9:32 PM EDT
Terminated No phase listed Observational

ChemoFx® PRO - A Post-Market Data Collection Study

NCT00669422
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Uterine Neoplasms, Endometrial Cancer, Vaginal Cancer, Vulvar Cancer, Cervical Cancer
Interventions
Not listed
Lead sponsor
Precision Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 2 Interventional

Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma

NCT00004066
View directory record Official record
Conditions
Ovarian Cancer, Sarcoma, Small Intestine Cancer
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 1 Interventional

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

NCT00060372
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Disseminated Neuroblastoma, Malignant Neoplasm, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Mixed Germ Cell Tumor, Ovarian Monodermal and Highly Specialized Teratoma, Ovarian Polyembryoma, Ovarian Yolk Sac Tumor, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Testicular Choriocarcinoma, Testicular Choriocarcinoma and Embryonal Carcinoma, Testicular Choriocarcinoma and Seminoma, Testicular Choriocarcinoma and Teratoma, Testicular Choriocarcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma, Testicular Embryonal Carcinoma and Seminoma, Testicular Embryonal Carcinoma and Teratoma, Testicular Embryonal Carcinoma and Teratoma With Seminoma, Testicular Embryonal Carcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma, Testicular Teratoma, Testicular Yolk Sac Tumor, Testicular Yolk Sac Tumor and Teratoma, Testicular Yolk Sac Tumor and Teratoma With Seminoma
Interventions
ipilimumab, therapeutic allogeneic lymphocytes
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
5
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 2 Interventional

Avatrombopag vs. Placebo for CIT in GI Malignancies

NCT05772546
View directory record Official record
Conditions
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
Interventions
Avatrombopag, Matching Placebo
Drug
Lead sponsor
Hanny Al-Samkari, MD
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 13, 2026, 9:32 PM EDT